Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25310617 | 0.91 | MAPT (0.41) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL25311946 | 0.88 | MAPT (0.41) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL25310980 | 0.87 | S1PR1 (0.38) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL25310570 | 0.87 | MAPT (0.40) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL25310293 | 0.86 | MAPT (0.40) | S1PR1S1PR3MAPTRENPOLB | |
| SCHEMBL25310429 | 0.84 | MAPT (0.40) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL26740096 | 0.82 | THRA (0.45) | S1PR1S1PR3MAPTRENTHRA | |
| SCHEMBL26740534 | 0.82 | THRA (0.42) | S1PR1S1PR3MAPTRENLMNA | |
| SCHEMBL26740605 | 0.81 | THRA (0.44) | S1PR1S1PR3MAPTRENTHRA | |
| SCHEMBL26739987 | 0.80 | THRB (0.49) | S1PR1S1PR3MAPTTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | S1PR1 696/4885S1PR3 902/4885MAPT 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.